CN1350521A - C16不饱和的fp选择性前列腺素类似物 - Google Patents
C16不饱和的fp选择性前列腺素类似物 Download PDFInfo
- Publication number
- CN1350521A CN1350521A CN00807185A CN00807185A CN1350521A CN 1350521 A CN1350521 A CN 1350521A CN 00807185 A CN00807185 A CN 00807185A CN 00807185 A CN00807185 A CN 00807185A CN 1350521 A CN1350521 A CN 1350521A
- Authority
- CN
- China
- Prior art keywords
- ring
- compound
- alkyl
- dihydro
- aromatic ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 150000001408 amides Chemical class 0.000 claims abstract description 3
- 150000002148 esters Chemical class 0.000 claims abstract description 3
- 150000003949 imides Chemical class 0.000 claims abstract description 3
- 230000003287 optical effect Effects 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 150000001721 carbon Chemical group 0.000 claims description 13
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 30
- 239000000203 mixture Substances 0.000 abstract description 19
- 208000020084 Bone disease Diseases 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- 238000006243 chemical reaction Methods 0.000 description 46
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 43
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 description 42
- -1 derivative of isopropyl ester Chemical class 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 150000003180 prostaglandins Chemical class 0.000 description 20
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 210000000988 bone and bone Anatomy 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- FAHUKNBUIVOJJR-UHFFFAOYSA-N 1-(4-fluorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1C1C2=CC=CN2CCN1 FAHUKNBUIVOJJR-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 238000004821 distillation Methods 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000003999 initiator Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000000935 solvent evaporation Methods 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000005605 benzo group Chemical group 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 150000004795 grignard reagents Chemical class 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 239000007818 Grignard reagent Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 3
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 150000003168 prostaglandin F1α derivatives Chemical class 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000002444 silanisation Methods 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000001384 anti-glaucoma Effects 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical group BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- JMVOCSLPMGHXPG-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium Chemical compound [K+].[K+].[O-][Os]([O-])(=O)=O JMVOCSLPMGHXPG-UHFFFAOYSA-N 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000012434 nucleophilic reagent Substances 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000010572 single replacement reaction Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- IUXHPSPHPKXTPA-UHFFFAOYSA-N 1-bromobut-1-ene Chemical compound CCC=CBr IUXHPSPHPKXTPA-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FDYKGJFSAUBIOO-UHFFFAOYSA-N 1h-indene-1-sulfonic acid Chemical group C1=CC=C2C(S(=O)(=O)O)C=CC2=C1 FDYKGJFSAUBIOO-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021718 Induced labour Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- VZDYWEUILIUIDF-UHFFFAOYSA-J cerium(4+);disulfate Chemical compound [Ce+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VZDYWEUILIUIDF-UHFFFAOYSA-J 0.000 description 1
- 229910000355 cerium(IV) sulfate Inorganic materials 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FGZJXVSDDHVZAH-UHFFFAOYSA-N ethoxyethane silane Chemical compound [SiH4].CCOCC FGZJXVSDDHVZAH-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000029860 luteolysis Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- ILQHFISNNSQESO-UHFFFAOYSA-N naphthalene;hydrobromide Chemical compound Br.C1=CC=CC2=CC=CC=C21 ILQHFISNNSQESO-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明提供新的PGF类似物。具体地说,本发明是关于结构为通式1的化合物,其中,R1、R2、X和Z如后文所述。本发明还包括该通式的光学异构体、非对映异构体和对映异构体,以及它们的药学上认可的盐,可生物水解的酰胺,酯和酰亚胺。本发明的化合物可用于治疗多种疾病,例如骨科疾病。于是,本发明还提供了包含这些化合物的药物组合物。本发明还提供用本发明化合物或组合物治疗骨科疾病的方法。
Description
发明领域
本发明涉及新的天然前列腺素的类似物。具体地说,本发明涉及新的前列腺素F类似物。本发明还涉及所述新前列腺素F类似物的使用方法。优选用途包括用于治疗骨科疾病和青光眼。
发明背景
天然前列腺素(PGA,PGB,PGE,PGF和PGI)属于C-20不饱和脂肪酸。PGF2α,即天然人前列腺素F,其特征在于碳脂环的C9和C11上是羟基,C5和C6之间是顺式双键,C13和C14之间是反式双键。因此,PGF2α的结构式为:
本领域已经有了天然前列腺素F的类似物。例如,1977年5月17日Bindra和Johnson的美国专利4,024,179,公开于1976年7月1日Beck,Lerch,Seeger和Teufel的德国专利DT-002,460,990;1978年12月5日Hayyashi,kori和Miyake的美国专利4,128,720;1977年3月8日Hess,Johnson,Bindra和Schaaf的美国专利4,011,262;1973年12月4日Bergstrom和Sjovall的美国专利3,776,938;P.W.Collins和S.W.Djuric,“治疗用前列腺素和前列环素类似物的合成”,化学评论,第93卷(1993),pp.1533-1564;G.L.Bundy和F.H.Lincoln,“17-苯基-18,19,20-三去甲前列腺素:I。PG1系列”,前列腺素,第9卷,第1期(1975),pp.1-4;W.Bartman,G.Beck和U.Lerch,H.Teufel和B.Scholkens,“黄体溶解性前列腺素:合成方法与生物活性”,前列腺素,第17卷,第2期(1979),pp.301-311;C.Liliebris,G.Selen,B.Resul,J.Sternschantz和U.Hacksell,“17-苯基-18,19,20-三去甲前列腺素F2α异丙酯的衍生物:潜在的抗青光眼药物”,药物化学杂志,第38卷,第2期(1995),pp.289-304。
已知天然前列腺素有多种药学特性。例如:前列腺素能松弛平滑肌,引起血管舒张和支气管舒张,能抑制胃酸分泌,抑制血小板凝结,降低眼内压,引产。虽然天然前列腺素是根据其对特定前列腺素受体的活性进行表征,但它们对任何一种特定前列腺素受体一般都没有特异性。所以,天然前列腺素在全身性使用时会引起例如炎症和表面刺激等副作用。普遍认为,天然前列腺素在体内释放后被迅速代谢,使它们的作用局限于一个区域。这能避免前列腺素激活全身前列腺素受体,因而象全身性给予天然前列腺素时那样引起副作用。
已知前列腺素,尤其是E类前列腺素(PGE)是骨吸收的强刺激剂。PGF2α也是骨吸收的刺激剂,但效力不及PGE2。此外,已知与PGE2相比,PGF2α对骨形成几乎没有作用。现在认为,PGF2α对骨吸收、骨形成和骨细胞复制的作用是内源性PGE2生成增强介导的。
由于天然前列腺素具有广泛的药学特性,但全身性给药时有副作用,所以一直希望能制备出对一个或数个受体具有特异性的天然前列腺素的类似物。本领域已经开发出许多此类类似物。虽然已有许多前列腺素类似物,但仍需要效力和选择性更高的前列腺素类似物用于治疗多种疾病。
发明概述
结构式A其中的R1,R2,X和Z如后文所述。
本发明还包括以上通式的光学异构体,非对映异构体和对映异构体,以及它们的药学上认可的盐,可生物水解的酰胺、酯和酰亚胺。
本发明化合物可用于治疗多种疾病,例如骨科疾病和青光眼。于是,本发明还提供包含以上化合物的药物组合物。本发明还提供用本发明化合物或组合物治疗骨科疾病和青光眼的方法。
本发明的详细描述术语和定义
“烃基”表示具有1-18个碳原子的饱和或不饱和烃链,以1-12个碳原子为佳,1-6个更好,1-4个最好。烃链可以是直链或支链。较好的支链烃基具有1到2个分支,以1个为佳。较好的是饱和烃链。不饱和烃基含有一个或多个双键和/或一个或多个三键。优选的不饱和烃基含一个或多个双键或一个三键,更好的是含一个双键。烃链可以是非取代的,或被1-4个取代基取代。优选的是单取代、二取代或三取代烃基。取代基可以是低级烃基,卤素,羟基,芳氧基(例如苯氧基),酰氧基(例如乙酰氧基),羧基,单芳环(例如苯基),单杂芳环,单脂肪环,单杂脂肪环,和氨基。
“低级烃基”指含1-6个碳原子的烃链,以1-3个为佳。
“芳环”即芳性烃环。芳环包括单环和稠双环系统。单芳环的环内含约5-10个碳原子,以5-7个为佳,5-6个最好。双芳环的环系统内含约8-12个碳原子,以9-10个为佳。双芳环包括其中之一为芳环的系统。优选的是两环都为芳性的环系统。芳环可以是非取代,或被1-4个取代基环上取代。取代基可以是卤素,氰基,烃基,杂烃基,卤烃基,苯基,苯氧基,或以上所述的组合。优选的取代基包括卤素和卤烃基。优选的芳环包括萘基和苯基。最好是苯基。
“碳脂环”指饱和或不饱和烃环。碳脂环不是芳性的。碳脂环是单环。碳脂环的环内含约4-10个碳原子,以4-7个为佳,5-6个最好。碳脂环可以是非取代的,也可被1-4个取代基环上取代。取代基可以是卤素,氰基,烃基,杂烃基,卤烃基,苯基,苯氧基,或以上所述的组合。优选的取代基包括卤素和卤烃基。优选的碳脂环包括环戊基,环己基,环己烯基,环庚基和环辛基。更好的碳脂环包括环己基,环庚基和环辛基。
“卤素”指氟、氯、溴、碘。以氟、氯和溴为佳,氯和氟更好,尤其是氟。
“卤烃基”指被一个或多个卤素取代的直链、支链或环烃基。所述卤烃基以C1-12为佳,C1-6更好,尤其是C1-3。优选的卤素取代基是氟和氯。最好的卤烃基是三氟甲基。
“杂烃基”指含碳原子和至少一个杂原子的饱和或不饱和链,其中,任两杂原子不毗邻。杂烃链的链内含1-18个原子(包括碳原子和杂原子),以1-12个为佳,1-6个更好,1-4还要好。杂烃链可以是支链或直链。优选的分支杂烃链有1到2个分支,以1个为佳。优选的杂烃基是饱和的。不饱和杂烃基含一个或多个双键和/或一个或多个三键。优选的不饱和杂烃基含1到2个双键或1个三键,只含1个双键更好。杂烃链可以是非取代的,或被1-4个取代基取代。优选的取代杂烃基是单取代、二取代或三取代的。取代基可以是低级烃基,卤素,羟基芳氧基(例如苯氧基),酰氧基(例如乙酰氧基),羧基,单芳环(例如苯基),单杂芳环,单碳脂环,单杂脂环,和氨基。
“低级杂烃基”指含有1-6个链内原子的烃链,以1-3个为佳。
“杂芳环”指环内含碳原子和1-4个杂原子的芳环。杂环包括单环和稠双环系统。单杂芳环的环内含5-10个原子(包括碳原子和杂原子),以5-7个为佳,5-6个最好。双杂芳环包括仅其中一环为芳性的系统。优选的是两环都为芳性的双杂芳环系统。双杂芳环含8-12个环内原子,最好是9或10个。杂芳环可以是非取代的,或被1-4个取代基环上取代。取代基可以是卤素、氰基、羟基、杂烃基、卤烃基、苯基、苯氧基,或以上取代基的组合。其中优选的是卤素、卤代烃基和苯基。优选的单杂芳环包括噻吩基,噻唑基,嘌呤基,嘧啶基,吡啶基,和呋喃基。更好的包括噻吩基,呋喃基和吡啶基。最好的是噻吩基。优选的双杂芳环包括苯并[β]噻唑基,苯并[β]噻吩基,喹啉基,喹喔啉基,苯并[β]呋喃基,苯并咪唑基,苯并噁唑基,吲哚基和苯邻甲内酰胺基(anthranilyl)。更好的双杂芳环包括苯并[β]噻唑基,苯并[β]噻吩基和苯并噁唑基。
“杂原子”指氮、硫或氧原子。含多个杂原子的基团所含的杂原子可以不同。
“杂脂环”指环内含碳原子和1-4个杂原子的饱和或不饱和环,其中环内任2个杂原子不相邻,连接杂原子的环内碳原子不再连有羟基、氨基或巯基。杂脂环不是芳性的。杂脂环是单环。杂脂环含约4-10个环原子(包括碳原子和杂原子),以4-7个为佳,5-6个最好。杂脂环可以是非取代的,或被1-4个取代基环上取代。取代基可以是卤素、氰基、烃基、杂烃基、卤烃基、苯基、苯氧基或以上所述的组合。优选的取代基包括卤素和卤烃基。优选的杂脂环包括piperzyl,吗啉基,四氢呋喃基,四氢吡喃基和哌啶基。
“苯基”指非取代或被1-4个取代基取代的单芳环。取代基可以稠合,但不可以桥连,并可取代在苯环的邻位、间位或对位,或以上所述的组合。取代基可以是卤素、酰基、氰基、烃基、杂烃基、卤烃基、苯基、苯氧基或以上所述的组合。苯环上优选的取代基包括卤素和卤烃基,最好的是卤素。苯环上优选的取代方式是邻位或间位取代,最好是间位取代。化合物
本发明包括具有以下结构的化合物:结构式A
以上结构中,R1是CO2H,C(O)NHOH,CO2R3,CH2OH,S(O)2R3,C(O)NHR3,C(O)NHS(O)2R4,或四唑;其中,R3是烃基,杂烃基,碳脂环,杂脂环,单芳环或单杂芳环,R4是烃基,杂烃基,碳脂环,杂脂环,单芳环或单杂芳环;优选的R3是甲基,乙基和异丙基。优选的R1是CO2H,C(O)NHOH,CO2R3,C(O)NHR3和四唑,最好的是CO2H和CO2R3。
以上结构中,R2是H或低级烃基,最好是H。
以上结构中,X是C≡C,或单键。
以上结构中,Z是芳环或杂芳环,条件是,当Z是杂芳环时,X是单键,Z通过环上碳原子与C15相连。当X是C≡C时,Z优选单芳环。当X是C≡C时,更好的Z是呋喃基,噻吩基和苯基。当X是单键时,Z优选二环杂芳环。
本发明还包括以上结构的异构体,非对映异构体和对映异构体。因此,在没有指明立构中心的立体化学时,两种差向异构体都包含在内。本发明化合物中此类立构中心的立体化学以类似于天然PGF2α的为佳。
结构式A1 结构式A2已发现,本发明的新PGF类似物能治疗骨科疾病,尤其是需要显著增加骨质量、骨体积和骨强度的那些。出人意料的是,本发明化合物与已知骨病疗法相比,具有以下优点:1)通过形成新的小梁增加小梁数;2)增加骨质量和体积的同时保持更接近正常的骨更新速度;和/或3)增强骨内膜表面处的骨形成,但不增加皮质空隙度。
为了测定和评价药学活性,用多种本领域己知的动物试验对本发明化合物进行了检测。例如,可以按照专用于检测化合物增加骨体积、质量或密度的试验来检验本发明化合物的骨活性。此类试验的例子之一是摘除卵巢的大鼠试验。
在摘除卵巢大鼠试验中,摘除6月龄大鼠的卵巢,2个月后,每日皮下给予一次待测化合物。研究结束时,用双能X光吸光测定法(DXA)或外周定量计算机化断层X射线照相(pQCT)或显微计算机化断层X射线照相(mCT)测定骨质量和/或密度。或者,可用静态和动态组织形态测定法来测定骨体积和骨形成的增加。
可用专用于测定被测化合物降低眼内压能力的试验来验证对青光眼的药学活性。此类试验的例子参见:C.Liljebres,G.Selen,B.Resul,J.Sternschantz和U.Hacksell,“17-苯基-18,19,20-三去甲前列腺素F2α异丙酯的衍生物:潜在的抗青光眼药物”,药物化学杂志,第38卷,第2期(1995),pp.289-304。
可通过常规有机合成方法来制造本发明化合物。以下总反应方案所描述的是一种优选的合成方法。
方案I其中,R1、R2、X和Z如前所述。作为方案I起始物的7[3-(R)-羟基-5-氧-1-环戊烯-1-基]庚酸甲酯(S1a)是购买的(可购自例如Sumitomo Chemical或CaymanChemical)。
用合适的保护基保护7-[3-(R)-羟基-5-氧-1-环戊烯-1-基]庚酸甲酯(S1a)的C11醇。优选的保护基是甲硅烷基。以上方案中,7-[3-(R)-羟基-5-氧-1-环戊烯-1-基]庚酸甲酯(S1a)在硅烷化溶剂中与硅烷化试剂和碱反应。优选的硅烷化试剂包括叔丁基二甲基氯甲硅烷和三氟甲烷磺酸叔丁基二甲基甲硅烷酯,最好是三氟甲烷磺酸叔丁基二甲基甲硅烷酯。优选的碱包括三乙基胺,三甲基胺和2,6-二甲基吡啶,更好的是三乙基胺和2,6-二甲基吡啶,最好是2,6-二甲基吡啶。优选的溶剂包括卤代烃溶剂,最好是二氯甲烷。反应宜在-100℃至100℃之间进行,以-80℃至80℃为佳,-70℃至23℃最好。
用常规方法分离生成的硅烷化化合物。此类方法包括但不限于萃取,溶剂蒸发,蒸馏和结晶。较好的是,分离后真空蒸馏纯化所述的硅烷醚。
然后该硅烷化化合物与铜酸盐反应,铜酸盐由合适的溴烯烃通过Grignard反应而成,参见H.O.House等,“碳负离子化学:生成锂有机铜酸盐的方便前体”,有机化学杂志Vol.40(1975),pp.1460-69;和P.Knochel等,“锌和铜卡宾体是有效的选择性a′/d′多偶联试剂”,美国化学协会杂志111(1989)p.6474-76。优选的溴烯烃包括4-溴-1-丁烯、4-溴-1-丁炔,4-溴-2-甲基-1-丁烯和4-溴-2-乙基-1-丁烯。溴烯烃最好是4-溴-1-丁烯。优选的溶剂包括醚类,其中优选乙醚和四氢呋喃,最好是四氢呋喃。可在100℃至23℃形成Grignard试剂,以85℃至30℃为佳,最好是75℃至65℃。反应时间以1-6小时为佳,2-5小时更好,3-4小时最好。
一旦Grignard试剂形成后,即由烯基镁形成铜酸盐。形成铜酸盐的温度为-100℃至0℃,以-80℃至-20℃为佳,更好的是-75℃至-50℃。优选的反应时间为30分钟至6小时,以45分钟至3小时为佳,最好是1小时至1.5小时。
由此形成的烯烃用常规技术来分离。这些方法包括但不限于萃取,溶剂蒸发,蒸馏和结晶。较好的是,在硅胶柱(Merck,230-400目)上,以10%EtOAc/己烷为洗脱剂,进行快速层析来纯化该烯烃。然后,该烯烃与氢化物还原剂和极性质子溶剂反应,生成C-9醇。优选的还原剂包括氢化锂铝,硼氢化钠和L-selectride,更好的是硼氢化钠和L-selectride,最好是硼氢化钠。优选溶剂包括甲醇,乙醇和丁醇,最好是甲醇。还原反应在-100℃至23℃之间进行,以-60℃至0℃为佳,最好是-45℃至-20℃。
用常规方法分离出所得的醇。此类方法包括但不限于萃取、溶剂蒸发、蒸馏和重结晶。优选在硅胶(Merck,230-400目)上,以20%EtOAc/己烷为洗脱液,通过快速层析来纯化醇。
可如前所述对所得的醇进行保护。此处优选的硅烷化试剂仍是叔丁基二甲基氯甲硅烷和三氟甲磺酸叔丁基二甲基甲硅烷酯。最好是三氟甲磺酸叔丁基二甲基甲硅烷酯。优选的碱包括三乙基胺,三甲基胺和2,6-二甲基吡啶。更好的是三乙基胺和2,6-二甲基吡啶。最好是2,6-二甲基吡啶。优选的溶剂包括卤代烃溶剂,最好是二氯甲烷。反应可在-100-100℃进行,以-80-80℃为佳,最好是-70-23℃。
用常规方法分离生成的甲硅烷化化合物。此类方法包括但不限于萃取、溶剂蒸发、蒸馏或重结晶。较好的是,分离后真空蒸馏纯化甲硅烷基醚。
然后,用某种形式的锇和高碘酸钠,在能够溶解这两者的溶剂中处理被保护的醇。优选的锇形式包括四氧化锇和锇酸钾。优选的溶剂系统包括乙酸与水的1∶1混合物,以及水、乙酸与THF的1∶1∶2混合物。处理的结果得到醛S1b。
用常规方法分离化合物S1b。这些方法包括但不限于萃取、溶剂蒸发、蒸馏和重结晶。优选在硅胶(Merck,230-400目)上,以20%EtOAc/己烷为洗脱液,通过快速层析来纯化S1b。
重要中间产物醛S1b可与多种不饱和碳亲核体反应生成C-9和C-11被保护的13,14-二氢-16-四去甲前列腺素F1α衍生物S1c。
与炔亲核试剂的反应宜在-80-0℃间进行,以-80--20℃为佳,-80--40℃更好。该反应的优选碱包括正丁基锂、仲丁基锂、叔丁基锂和二异丙基氨化锂(LDA),最好的是正丁基锂。该反应的优选溶剂是醚溶剂,包括乙醚和四氢呋喃,以四氢呋喃最佳。对杂环亲核试剂来说,优选的溶剂是醚,以乙醚、丁醚和四氢呋喃为佳,以四氢呋喃为最佳。
然后可用已知方法进行化合物S1c的去保护。分离后得到13,14-二氢-15-取代-15-五去甲前列腺素F1α衍生物,如结构式I所示。结构式I代表的化合物可参见实施例1-43。
用已知方法,可由化合物S1c即C9和C11被保护的13,14-二氢-16-四去甲前列腺素F1α衍生物直接制得结构式II所示的化合物。例如,甲酯S1c与胺或羟基胺缩合可生成结构式II所示的化合物。结构式II代表的化合物可参见实施例44-47。可用常规方法分离上述化合物。这些方法包括但不限于萃取、溶剂蒸发、蒸馏和结晶。
以下非限定性实施例说明本发明的化合物、组合物和用途。
实施例
用1H和13C NMR、元素分析、质谱、高分辨率质谱和/或IR光谱分析化合物。
通常,使用惰性溶剂(以无水的为佳),例如,钠和二苯甲酮蒸馏得到四氢呋喃(THF),氢化钙蒸馏得到二异丙基胺,其它溶剂都是购买的适当级别的商品。层析在适当的硅胶(70-230目;Aldrich)或(230-400目;Merck)上进行。在玻载硅胶板(200-300目;J.T.Baker)上进行薄层层析,并用5%磷钼酸的EtOH溶液,或用钼酸铵/硫酸高铈在10%H2SO4水溶液中所成的溶液,UV光下显示。
实施例1
在-78℃,向7-[3-(R)-羟基-5-氧-1-环戊烯-1-基]庚酸甲酯S2a(1当量)的CH2Cl2溶液中用15分钟滴加2,6-二甲基吡啶(1.3当量)。将溶液保温在-78℃。用15分钟滴加TBDMS三氟甲磺酸酯(Triflate)(1.2当量)的CH2Cl2溶液。将反应逐渐升至室温,并室温搅拌15小时。加入10%HCl水溶液,分层。用CH2Cl2萃取水层,合并有机层。有机层用盐水洗涤,干燥(Na2SO4),并浓缩。残留物经真空(10mmHg)蒸馏,得甲硅烷基醚S2b。b.7-(5-丁-3-烯基-2-羟基-4-(1,1,2,2-四甲基-1-硅杂丙氧基)环戊基)庚酸甲酯(S2c):
室温下,向Mg粉末(2当量)的THF浆中加入晶体碘(催化剂l2),并用10分钟滴加1-溴丁烯(2当量)。反应在加入过程中不断放热。加完后,回流3小时,冷却至室温。用THF稀释该Grignard试剂,在-78℃,通过套管加到配有机械搅拌的三颈烧瓶中,其中已加有溶于THF/DMS 1∶1溶液的CuBr.DMS(2当量)。加入Grignard试剂(约20分钟)后,-78℃搅拌反应1小时。反应此时呈暗红色。然后用25分钟滴加酮S2b(1当量)的THF溶液。-78℃搅拌反应15分钟,然后经2小时缓慢升至室温。用NH4Cl水溶液终止反应,通宵蒸发过量的DMS。将反应液在盐水/CH2Cl2之间分配,分层。用CH2Cl2反萃水层,合并有机层,干燥(Na2SO4)。真空去除溶剂,残留物经SiO2(10%己烷/EtAOc)层析得S2c的酮前体。
将该S2c的酮前体(1当量)溶于MeOH,冷却至-40℃。用10分钟分批加入硼氢化钠(0.9当量)。加完后,-40℃搅拌反应13小时,然后在-78℃反应12小时。用水终止反应,在盐水/CH2Cl2之间分配,分层。用CH2Cl2反萃水层,合并有机层,干燥(Na2SO4)。真空去除溶剂,残留物经SiO2(30%EtAOc/己烷)层析得醇S2c。c.7-(5-丁-3-烯基-2,4-二(1,1,2,2-四甲基-1-硅杂丙氧基)环戊基)庚酸甲酯(S2d):
将醇S2c(1当量)溶于CH2Cl2,冷却至0℃,用15分钟滴加2,6-二甲基吡啶(1.3当量)。溶液保温在-78℃,用15分钟滴加TBDMS三氟甲磺酸酯(1.2当量)的CH2Cl2溶液。将反应逐渐升至室温,并搅拌15小时。加入10%HCl水溶液,分层。用CH2Cl2萃取水层,合并有机层。有机层用盐水洗涤,干燥(Na2SO4),并浓缩。残留物经层析(10% EtOAc/己烷)得甲硅烷基醚S2d。d.7-(5-(3-氧丙烷基)-2,4-二(1,1,2,2-四甲基-1-硅杂丙氧基)环戊基)庚酸甲酯(S2e):
在50ml的园底烧瓶中加入过碘酸钠(2当量)和10ml水。搅拌至过碘酸盐完全溶解。然后加入等量冰醋酸,接着加入2份四氢呋喃。最后加入几摩尔百分比的锇酸钾,接着加入烯S2d(1当量)。在室温氮气氛下搅拌反应,用TLC监测反应。当TLC显示不再有起始物时,用盐水终止反应,并用4∶1的乙酸乙酯/己烷萃取。有机相用盐水洗至中性,硫酸钠干燥,并浓缩。经柱层析(7∶3 己烷∶乙酸乙酯)后得S2e。e.7-(5-(3-羟基-3-硫茚基-丙烷基)-2,4-二(1,1,2,2-四甲基-1-硅杂丙氧基)环戊基)庚酸甲酯(S2f):
将S2e溶于数毫升的无水THF,将此溶液滴加到-78℃硫茚基阴离子锂(正丁基锂与硫代茚在-78℃反应而成)的THF溶液中(装于一50ml圆底烧瓶中)。搅拌反应,直至TLC显示反应完成。在-78℃用饱和氯化铵溶液终止反应,用4∶1的乙酸乙酯与己烷混合物萃取。有机层用盐水洗涤至pH中性,用硫酸钠干燥,然后浓缩。经柱层析(7∶3的己烷∶乙酸乙酯)得S2f。f.13,14-二氢-15-(硫茚基)-15-五去甲前列腺素F1α(S2g):
在一园底小烧瓶中加入甲酯S2f和3ml CH3CN。然后加入0.1ml HF/吡啶(0.1mmol,1当量),同时将烧瓶由0℃升至室温。21℃反应3小时后,用饱和NaCl水溶液终止反应。用CH2Cl2萃取水层3次。合并有机层,用1N HCl洗涤三次,用盐水洗涤,干燥(Na2SO4)。柱层析(7∶3的己烷∶乙酸乙酯)得澄清油状物。将该油状物加入数毫升3∶1的THF∶水溶液中,将烧瓶冷却至0℃。加入过量(2.5当量)氢氧化锂,移走冰浴,室温下搅拌反应过夜。在反应混合物中加入二氯甲烷和饱和柠檬酸,水层用二氯甲烷洗涤3次,合并有机层,用盐水洗涤,干燥(Na2SO4),真空浓缩,残留物经层析(二氯甲烷/甲醇/乙酸:9.6/0.4/0.015),得S2g。
实施例2-22
代之以合适的起始物,参照实施例1来制备实施例2-22。本领域技术人员能够适当改变反应的温度、压力、气氛、溶剂或顺序。此外,本领域技术人员可适当用保护基阻断副反应或提高得率。有机化学技术人员均可方便的实施所有以上修改,因此,这些都属于本发明范围之内。
实施例2
实施例3
实施例4
13,14-二氢-16-炔基-17-(2,5-二氟苯基)-17-三去甲前列腺素F1α
实施例5
实施例6
13,14-二氢-16-炔基-17-(3,5-二氟苯基)-17-三去甲前列腺素F1α
实施例7
13,14-二氢-16-炔基-17-(3,4-二氟苯基)-17-三去甲前列腺素F1α
实施例8
13,14-二氢-15-(6-氟硫茚基)-15-五去甲前列腺素F1α
实施例9
实施例10
13,14-二氢-16-炔基-17-(3-氟苯基)-17-三去甲前列腺素F1α甲酯
实施例11
实施例12
13,14-二氢-16-炔基-17-(4-氯苯基)-17-三去甲前列腺素F1α
实施例13
13,14-二氢-16-炔基-17-苯基-17-三去甲前列腺素F1α异丙酯
实施例14
实施例15
13,14-二氢-15-(5-氟苯并噻唑基)-15-五去甲前列腺素F1α异丙酯
实施例16
实施例17
13,14-二氢-16-炔基-17-(2-氟苯基)-17-三去甲前列腺素F1α甲酯
实施例18
实施例19
实施例20
13,14-二氢-16-炔基-18-苯基-18-二去甲前列腺素F1α
实施例21
实施例22
13,14-二氢-16-炔基-18-(2-氟苯基)-18-二去甲前列腺素F1α
实施例23
将实施例1中的醛S2e溶于数毫升无水THF,将其加入-78℃的Grignard试剂(镁与溴代苯0℃缩合而成)THF溶液中(装于一50ml圆底烧瓶中)。搅拌反应,直至TLC显示反应完成。在-78℃用氯化铵饱和溶液终止反应,用4∶1的乙酸乙酯∶己烷萃取。有机层用盐水洗涤至pH中性,硫酸钠干燥,浓缩。经柱层析(7∶3的己烷∶乙酸乙酯)得S3a。b.13,14-二氢-15-苯基-15-五去甲前列腺素F1α(S3b):
在一圆底小烧瓶中加入甲酯S3a和3ml CH3CN,以及0.1ml HF/吡啶(0.1mmol,1当量),同时将烧瓶由0℃升至室温。21℃反应3小时后,用饱和NaCl水溶液终止反应。用CH2Cl2萃取水层3次。合并有机层,用1N HCl洗涤三次,用盐水洗涤,干燥(Na2SO4)。柱层析(97∶3的二氯甲烷∶甲醇)得澄清油状物。将该油状物加入数毫升3∶1的THF∶水溶液中,将烧瓶冷却至0℃。加入过量(2.5当量)氢氧化锂,移走冰浴,室温下搅拌反应过夜。在反应混合物中加入二氯甲烷和饱和柠檬酸,水层用二氯甲烷洗涤3次,合并有机层,用盐水洗涤,干燥(Na2SO4),真空浓缩,残留物经层析(二氯甲烷/甲醇/7酸:9.6/0.4/0.015),得S3b。
实施例24-35
代之以合适的起始物,参照实施例23来制备实施例24-35。本领域技术人员能够适当改变反应的温度、压力、气氛、溶剂或顺序。此外,本领域技术人员可适当用保护基阻断副反应或提高得率。有机化学技术人员均可方便的实施所有以上修改,因此,这些都属于本发明范围之内。
实施例24
实施例25
实施例26
实施例27
实施例28
实施例29
13,14-二氢-15-(3-氯-4-氟-6-甲基苯基)-15-五去甲前列腺素F1α
实施例30
实施例31
实施例32
实施例33
实施例34
实施例35
实施例36
13,14-二氢-15-(6-甲基萘-2-基)-15-五去甲前列腺素F1α的制备a.7-(5-(3-羟基,(4-甲基-2-萘基)-丙基)-2,4-二(1,1,2,2-四甲基-1-硅杂丙氧基)环戊基)庚酸甲酯(S4a):
将实施例1中的醛S2e溶于数毫升无水THF,将其加入-78℃的萘基阴离子(叔丁基锂与溴代萘在-78℃反应生成)无水THF溶液中(装于一50ml圆底烧瓶中)。搅拌反应,直至TLC显示反应完成。在-78℃用氯化铵饱和溶液终止反应,用4∶1的乙酸乙酯∶己烷萃取。有机层用盐水洗涤至pH中性,硫酸钠干燥,浓缩。经柱层析(7∶3的己烷∶乙酸乙酯)得S4a。b.13,14-二氢-16,17-脱氢-15-(6-甲基-2-萘基)-15-五去甲前列腺素F1α(S4b):
在一圆底小烧瓶中加入甲酯S4a和3ml CH3CN,以及0.1ml HF/吡啶(0.1mmol,1当量),同时将烧瓶由0℃升至室温。21℃反应3小时后,用饱和NaCl水溶液终止反应。用CH2Cl2萃取水层3次。合并有机层,用1N HCl洗涤三次,用盐水洗涤,干燥(Na2SO4)。柱层析(97∶3的二氯甲烷∶甲醇)得澄清油状物。将该油状物加入数毫升3∶1的THF∶水溶液中,将烧瓶冷却至0℃。加入过量(2.5当量)氢氧化锂,移走冰浴,室温下搅拌反应过夜。在反应混合物中加入二氯甲烷和饱和柠檬酸,水层用二氯甲烷洗涤3次,合并有机层,用盐水洗涤,干燥(Na2SO4),真空浓缩,残留物经层析(二氯甲烷/甲醇/乙酸:9.6/0.4/0.015),得S4b。
实施例27-42
代之以合适的起始物,参照实施例36来制备实施例27-42。本领域技术人员能够适当改变反应的温度、压力、气氛、溶剂或顺序。此外,本领域技术人员可适当用保护基阻断副反应或提高得率。有机化学技术人员均可方便的实施所有以上修改,因此,这些都属于本发明范围之内。
实施例37
13,14-二氢-15-(苯并[b]噻吩-5-基)-15-五去甲前列腺素F1α
实施例38
13,14-二氢-15-(6-苯并噻唑-5-基)-15-五去甲前列腺素F1α
实施例39
实施例40
13,14-二氢-15-(5-氟萘基)-15-五去甲前列腺素F1α
实施例41
实施例42
实施例43
13,14-二氢-15-(1-氟-3-三氟甲基-2-萘基)-15-五去甲前列腺素F1α异丙酯
实施例44
火焰干燥-25ml的圆底烧瓶,该烧瓶配有磁力搅拌棒,在其中加入13,14-二氢-16,17-二脱氢-17-邻氟苯基三去甲前列腺素F1α甲酯(实施例17)(1.0当量)的甲醇溶液。向该溶液中加入羟基胺的甲醇溶液(1.25当量)。搅拌数分钟,然后与1N盐酸反应,然后用乙酸乙酯萃取。有机层用盐水洗涤,硫酸镁干燥,过滤,减压浓缩。残留物经层析,得13,14-二氢-16-炔基-17-(2-氟苯基)-17-三去甲前列腺素F1α1-异羟肟酸
实施例45-47
代之以合适的起始物,参照实施例44来制备实施例45-47。本领域技术人员能够适当改变反应的温度、压力、气氛、溶剂或顺序。此外,本领域技术人员可适当用保护基阻断副反应或提高得率。有机化学技术人员均可方便的实施所有以上修改,因此,这些都属于本发明范围之内。
实施例45
13,14-二氢-15-(苯并噻唑基)-15-五去甲前列腺素F1α1-异羟肟酸
实施例46
实施例47
本发明组合物包含安全有效量的标题化合物和药学上认可的载体。本发明中,“安全有效量”表示化合物的量在经可靠医学判断认可的范围内,就显著改善所治病情而言足够高,但就避免严重副作用而言足够低(具有合理的效/险比)。化合物的安全有效量取决于具体的待治疾病,患者的年龄和身体状况,疾病的严重程度,疗程长短,当前疗法的特性,具体所用的药学上认可的载体等因素,这些都是医护人员所熟知的。
除所述化合物之外,本发明组合物还包含“药学上认可的载体”。“药学上认可的载体”指适合给予患者的一种或多种相容性固体或液体充填性稀释剂或包胶物质。“相容性”在此表示所述组合物的组分能够与所述化合物混合,并能够彼此混合,其间没有会在一般使用条件下严重降低组合物药效的相互反应。当然,药学上认可的载体必须具有足够高的纯度和足够低的毒性,从而适合给予接受治疗的患者。
所述药学上认可的的载体或组分有例如:乳糖、葡萄糖和蔗糖等糖类;玉米淀粉和马铃薯淀粉等淀粉;羧甲基纤维素钠、乙基纤维素、纤维素乙酸酯等纤维素及其衍生物;粉状黄著胶;麦芽糖;明胶;滑石粉、硬脂酸、硬脂酸镁等固体润滑剂;硫酸钙;花生油、棉籽油、芝麻油、橄榄油、玉米油和可可油等植物油;丙二醇、甘油、山梨醇、甘露醇和聚乙二醇等多元醇;藻酸;Tween等乳化剂;十二烷基硫酸钠等润湿剂;色素;赋味剂;赋形剂;成片剂;稳定剂;抗氧化剂;防腐剂;无热原水;等渗盐水和磷酸盐缓冲液。
选择何种药学上认可的载体与某化合物联用主要取决于该化合物的给药途径。本发明化合物可以全身性给予。给药途径包括透皮、口服、皮下或静脉注射等非肠胃途径、局部、和/或鼻内。
化合物的用量可用动物模型进行常规试验来确定。此类模型包括但不限于健全和摘除了卵巢的大鼠模型,也可使用白鼬、狗和非人类灵长动物以及废模型。
优选的注射用单位剂型包括化合物的无菌水溶液,生理盐水溶液,或两者混合配制的溶液。所述溶液的pH应调节至7.4。适用于注射和手术移植的载体包括水凝胶、控释或缓释装置、聚乳酸和胶原基质。
适用于局部使用的药学上认可的载体包括擦剂、霜剂和凝胶剂等中适用的那些。如欲口服给予化合物,则优选片剂、胶囊等单位剂型。适合制备口服单位剂型的药学上认可的载体众所周知,其选择取决于口味、成本和保存期等对本发明目的影响不大的次级考虑因素,本领域技术人员不难做出此类选择。使用方法
本发明化合物可用于治疗多种疾病,例如眼病、高血压、生育控制、鼻充血、神经性膀胱疾病、胃肠疾病、皮肤病和骨质疏松。
本发明化合物可通过形成新的梁骨和骨质来增加骨体积和增加梁骨数量,同时保持正常的骨更新速度,并且,所述形成发生于骨内膜表面,不损失已有皮质中的骨质。因此,本发明化合物可用于治疗和预防骨科疾病。
治疗骨病的优选给药途径是透皮和鼻内,还包括直肠、舌下和口服。
全身性给予化合物的剂量范围约为每日每公斤体重0.1-1000μg,以0.1-100μg为佳,1-50μg为最佳。根据药物动力学和透皮制剂方面的已有知识,透皮剂量应能达到达到与以上所述相当的血清和血浆水平。全身性给予的血浆水平应在0.01-100ng/ml之间,以0.05-50ng/ml为佳,0.1-10ng/ml为最佳。虽然以上所述为日用剂量,但也可用周或月剂量来计算临床所需的用药量。
为获得所需的效果,剂量可根据患者、疾病、病情、给药途径等而改变。
本发明化合物还可用于降低眼内压。因此,本发明化合物还可用于治疗青光眼。治疗青光眼的优选给药途径是局部使用。组合物和方法实施例
以下非限定性实施例描述了本发明。以下组合物和方法举例不限定本发明的范围,仅指导技术人员如何制备和运用本发明的化合物、组合物和方法。在各种情况中,都可用本发明的其它化合物来取代所例举的化合物,获得相近的效果。熟练技术人员将看出,以下实施例提供的是引导,可根据具体疾病和患者加以变化。
实施例A
用混合后直接压片等常规方法制备片剂型药物组合物,配方如下:
成分 含量(毫克/片)
实施例1化合物 5
微晶纤维素 100
淀粉乙醇酸钠 30
硬脂酸镁 3
给一骨质疏松患者每日口服一次,该组合物显著增加了骨体积。
实施例B
用常规方法制备液剂型药物组合物,配方如下:
成分 含量
实施例32化合物 1mg
磷酸盐缓冲的生理盐水 10ml
对羟基苯甲酸甲酯 0.05ml
给一骨质疏松患者每日皮下注射一次1.0ml该组合物,该组合物显著最佳了骨体积。
实施例C
用常规方法制备用于降低眼内压的外用药物组合物,配方如下:
成分 含量(wt%)
实施例1化合物 0.004
葡聚糖70 0.1
羟丙基甲基纤维素 0.3
氯化钠 0.77
氯化钾 0.12
EDTA二钠 0.05
氯化苯甲烃铵 0.01
HCl和/或NaOH pH7.2-7.5
纯水 补足100%
虽然以上具体描述了本发明的实施方式,但本领域技术人员可以看出,在本发明范围内可对所述的组合物进行多种改变。因此,权利要求书意欲使得本发明的范围涵盖所有这些改变。
Claims (10)
1.一种化合物,具有以下结构:其中,(a)R1选自CO2H,C(O)NHOH,CO2R3,CH2OH,S(O)2R3,C(O)NHR3,C(O)NHS(O)2R4或四唑;其中,R3是烃基,杂烃基,碳脂环,杂脂环,单芳环或单杂芳环,R4是烃基,杂烃基,碳脂环,杂脂环,单芳环或单杂芳环;
(b)R2是H或低级烃基;
(c)X是:
(1)C≡C,或
(2)单键;
(d)Z是芳环或杂芳环,当Z是杂芳环时,X是单键,Z通过环上碳原子与C15相连;
(e)上述结构的光学异构体,非对映体和对映体,以及上述化合物的药学上认可的盐、可生物水解的酰胺、酯或酰亚胺。
2.根据权利要求1所述的化合物,其中的Z是单环。
3.根据权利要求1所述的化合物,其中的Z是二环杂芳环。
4.根据前述权利要求中任一项所述的化合物,其中的R1是CO2H,C(O)NHOH,CO2R3,C(O)NHS(O)2R4或四唑。
5.根据前述权利要求中任一项所述的化合物,其中的R2是H。
6.根据前述权利要求中任一项所述的化合物,其中的X是C≡C。
7.根据前述权利要求中任一项所述的化合物,其中的Z被单取代,该取代基选自低级烃基,卤素和卤代烃基。
8.前述权利要求中任一项所述化合物的用途,即用于制造治疗骨科疾病的药物。
9.根据权利要求8所述的用途,所述骨科疾病是骨质疏松。
10.权利要求1,2,3,4,5,6或7所述化合物的用途,即用于制造治疗青光眼的药物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12292499P | 1999-03-05 | 1999-03-05 | |
US60/122,924 | 1999-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1350521A true CN1350521A (zh) | 2002-05-22 |
Family
ID=22405663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00807185A Pending CN1350521A (zh) | 1999-03-05 | 2000-02-29 | C16不饱和的fp选择性前列腺素类似物 |
Country Status (20)
Country | Link |
---|---|
US (2) | US6586463B2 (zh) |
EP (1) | EP1159266B1 (zh) |
JP (2) | JP4834224B2 (zh) |
KR (1) | KR20010108316A (zh) |
CN (1) | CN1350521A (zh) |
AT (1) | ATE281432T1 (zh) |
AU (1) | AU766163B2 (zh) |
BR (1) | BR0008776A (zh) |
CA (1) | CA2364948C (zh) |
CO (1) | CO5160251A1 (zh) |
CZ (1) | CZ20013174A3 (zh) |
DE (1) | DE60015508T2 (zh) |
ES (1) | ES2232434T3 (zh) |
HU (1) | HUP0200258A2 (zh) |
IL (1) | IL145122A0 (zh) |
MX (1) | MXPA01008955A (zh) |
NO (1) | NO20014241L (zh) |
NZ (1) | NZ513825A (zh) |
PL (1) | PL350917A1 (zh) |
WO (1) | WO2000051980A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108084074A (zh) * | 2017-12-25 | 2018-05-29 | 厦门欧瑞捷生物科技有限公司 | 一种简便高效合成地诺前列素的方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4834224B2 (ja) | 1999-03-05 | 2011-12-14 | デューク ユニバーシティ | C16不飽和fp−選択的プロスタグランジン類縁体 |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US6531504B2 (en) * | 2001-05-17 | 2003-03-11 | Allergan, Inc. | Prostanoic acid derivatives as agents for lowering intraocular pressure |
WO2002102389A1 (en) * | 2001-06-14 | 2002-12-27 | Allergan, Inc. | 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
WO2006047466A2 (en) * | 2004-10-21 | 2006-05-04 | Duke University | Ophthamological drugs |
US20070254920A1 (en) * | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
US7960431B2 (en) * | 2007-02-01 | 2011-06-14 | Allergan, Inc. | Thiophenyl prostaglandin derivatives for treating glaucoma and ocular hypertension |
US7964595B2 (en) * | 2008-01-18 | 2011-06-21 | Allergan, Inc. | Thiophenyl prostaglandin derivatives for treating glaucoma and ocular hypertension |
US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
Family Cites Families (286)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US146439A (en) | 1874-01-13 | Improvement in pruning-shears | ||
US37913A (en) | 1863-03-17 | Improvement in sewing-machines | ||
US37914A (en) | 1863-03-17 | Improved automatic nose-bag | ||
US13294A (en) | 1855-07-17 | Improved apparatus for cooling repeating fire-arms | ||
DE1617477U (de) | 1950-09-27 | 1950-12-14 | Heinrich Dressel | Radhalter fuer raeder, beispielsweise fuer kinderwagen und kleinfahrzeuge. |
US3776938A (en) | 1958-05-28 | 1973-12-04 | S Bergstrom | Dihydro-pge1 |
US3776939A (en) | 1958-05-28 | 1973-12-04 | S Bergstrom | Dihydro-pgf1a |
US3069322A (en) | 1958-05-28 | 1962-12-18 | Bergstrom Sune | Pge and pgf |
US3839409A (en) | 1958-05-28 | 1974-10-01 | Kemiska Inst Karolinska I | Pge3 esters and alkanoates |
US3461461A (en) | 1965-11-01 | 1969-08-12 | Upjohn Co | 6-amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidines |
US3524867A (en) | 1966-06-06 | 1970-08-18 | Upjohn Co | Process for producing cyclopenta (b)pyrans |
US3435053A (en) | 1966-06-06 | 1969-03-25 | Upjohn Co | Cyclopenta(b)pyrans |
US3538120A (en) | 1967-05-22 | 1970-11-03 | Ciba Geigy Corp | Cyclopentyl-alkanoic acids |
US3636120A (en) | 1967-10-09 | 1972-01-18 | Upjohn Co | Prostaglandin e primary alcohols |
GB1285371A (en) | 1968-08-29 | 1972-08-16 | Upjohn Co | Improvements in or relating to therapeutic methods using prostaglandins |
GB1251750A (zh) | 1968-11-12 | 1971-10-27 | ||
DE1910561A1 (de) | 1969-03-01 | 1970-09-10 | Herten Dr Med Kurt | Mittel zur Verhuetung von Haarausfall |
BE755555A (fr) | 1969-09-02 | 1971-03-01 | Richardson Merrell Inc | Derives de quinoxaline |
US3882241A (en) | 1969-12-01 | 1975-05-06 | Upjohn Co | Use of prostaglandins E and F for prevention of pregnancy in humans |
US3896156A (en) | 1970-06-30 | 1975-07-22 | Upjohn Co | Dihydroprostaglandin e, analogs |
IT1012505B (it) | 1970-09-28 | 1977-03-10 | Imes C Spa | Estratto di ricci di mare |
BE791369A (fr) | 1971-11-16 | 1973-05-14 | American Cyanamid Co | Cyanurates de tris-(meta-hydroxybenzyle) faisant l'objet d'un empechement sterique et utilisables comme anti-oxydants |
US3798275A (en) | 1972-04-05 | 1974-03-19 | Ciba Geigy Corp | Etherified mercapto-methoxyamines |
GB1386146A (en) * | 1972-05-03 | 1975-03-05 | Ici Ltd | Cyclopentane derivatives |
US3974213A (en) * | 1972-07-13 | 1976-08-10 | Pfizer Inc. | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins |
US4011262A (en) * | 1972-07-13 | 1977-03-08 | Pfizer Inc. | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series |
GB1428137A (en) * | 1972-09-27 | 1976-03-17 | Ici Ltd | Prostanoic acid derivatives |
JPS4969636U (zh) | 1972-09-29 | 1974-06-18 | ||
US3882245A (en) | 1972-11-01 | 1975-05-06 | Upjohn Co | Use of prostaglandins in combating shock |
US4152527A (en) | 1972-11-08 | 1979-05-01 | Pfizer Inc. | 15-Substituted-ω-pentanorprostaglandins |
IL43571A (en) * | 1972-11-08 | 1977-08-31 | Pfizer | Omega-pentanorprostaglandins and their preparation |
DD118856A5 (zh) | 1972-11-08 | 1976-03-20 | ||
US3984424A (en) * | 1972-11-08 | 1976-10-05 | Pfizer Inc. | P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins |
US4024179A (en) | 1972-11-08 | 1977-05-17 | Pfizer Inc. | Substituted ω-pentanorprostaglandins |
JPS4993342U (zh) | 1972-12-05 | 1974-08-13 | ||
JPS5253841Y2 (zh) | 1972-12-12 | 1977-12-07 | ||
JPS49101356U (zh) | 1972-12-20 | 1974-08-31 | ||
JPS5320995Y2 (zh) | 1972-12-23 | 1978-06-02 | ||
JPS5720305B2 (zh) | 1973-02-28 | 1982-04-27 | ||
US3984455A (en) | 1973-07-16 | 1976-10-05 | The Upjohn Company | Prostaglandin E1 analogs |
FR2239458A1 (en) | 1973-07-31 | 1975-02-28 | Aries Robert | Prostaglandin amides - with antilipolytic, gonadotrophic, luteolytic, hypotensive and other activities associated with prostaglandins |
DE2365101A1 (de) * | 1973-12-21 | 1975-07-10 | Schering Ag | Neue prostansaeurederivate und verfahren zu ihrer herstellung |
US3928588A (en) | 1974-02-22 | 1975-12-23 | Upjohn Co | Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors |
JPS50157344A (zh) * | 1974-03-20 | 1975-12-19 | ||
DE2416193C2 (de) | 1974-04-03 | 1985-08-14 | Hoechst Ag, 6230 Frankfurt | Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel |
GB1458315A (en) * | 1974-04-22 | 1976-12-15 | Ici Ltd | Prostanoic acid derivatives |
DE2460990A1 (de) | 1974-12-21 | 1976-07-01 | Hoechst Ag | Neue prostaglandin-analoga und verfahren zu ihrer herstellung |
JPS5186449U (zh) | 1974-12-30 | 1976-07-10 | ||
GB1507211A (en) | 1975-02-14 | 1978-04-12 | Ono Pharmaceutical Co | Prostaglandin analogues |
US3934013A (en) | 1975-02-21 | 1976-01-20 | Syntex (U.S.A.) Inc. | Pharmaceutical composition |
US4217360A (en) | 1975-02-27 | 1980-08-12 | Schering Aktiengesellschaft | Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof |
GB1506817A (en) | 1975-03-31 | 1978-04-12 | Upjohn Co | Prostaglandins |
DE2517771A1 (de) | 1975-04-18 | 1976-10-28 | Schering Ag | Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung |
JPS5328160Y2 (zh) | 1975-05-16 | 1978-07-15 | ||
GB1517562A (en) * | 1975-06-13 | 1978-07-12 | Ici Ltd | Prostane derivatives |
GB1520522A (en) | 1975-06-16 | 1978-08-09 | Ono Pharmaceutical Co | 16-methyleneprostaglandins |
US4128577A (en) | 1975-12-29 | 1978-12-05 | The Upjohn Company | 15-Methyl- and 16-phenoxy-PGF2 α, amides |
US4158667A (en) | 1976-02-04 | 1979-06-19 | The Upjohn Company | 6-Keto PGF analogs |
US4139619A (en) | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
US4596812A (en) | 1976-05-24 | 1986-06-24 | The Upjohn Company | Methods and solutions for treating male pattern alopecia |
US4051238A (en) | 1976-06-03 | 1977-09-27 | The Upjohn Company | Treatment of genital tract diseases of domestic animals with prostaglandins |
US4268522A (en) | 1976-06-14 | 1981-05-19 | Pfizer Inc. | 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof |
DE2635985A1 (de) | 1976-08-06 | 1978-02-09 | Schering Ag | Prostansaeurederivat und verfahren zu ihrer herstellung |
DE2737808A1 (de) | 1976-08-27 | 1978-03-16 | Pfizer | 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine |
DE2737807A1 (de) * | 1976-08-27 | 1978-03-09 | Pfizer | C tief 1 -p-biphenylester von omega-pentanorprostaglandinen |
US4123441A (en) | 1976-09-22 | 1978-10-31 | The Upjohn Company | Enlarged-hetero-ring prostacyclin analogs |
US4499293A (en) | 1976-09-22 | 1985-02-12 | The Upjohn Company | PGI2 Salts |
US4089885A (en) | 1976-11-05 | 1978-05-16 | American Home Products Corporation | Prostaglandin derivatives |
US4171331A (en) | 1978-06-05 | 1979-10-16 | Miles Laboratories, Inc. | 1 And 2-substituted analogues of certain prostaglandins |
US4206151A (en) | 1978-12-21 | 1980-06-03 | American Cyanamid Company | 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series |
US4311707A (en) | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
GB2048254B (en) | 1979-04-02 | 1983-05-25 | Upjohn Co | 19,20 -didehydro-19-hydroxy and 19-oxo-prostaglandin derivatives |
JPS5829710Y2 (ja) | 1979-05-25 | 1983-06-29 | スガツネ工業株式会社 | 錠前 |
US4225507A (en) | 1979-07-05 | 1980-09-30 | The Upjohn Company | 19-Hydroxy-19-methyl-PGI2 compounds |
US4225508A (en) | 1979-07-05 | 1980-09-30 | The Upjohn Company | 19-Hydroxy-PGI2 compounds |
US4296504A (en) | 1980-07-07 | 1981-10-27 | Lawson Daniel C | Toilet seat lock |
JPH0222226Y2 (zh) | 1981-02-04 | 1990-06-14 | ||
US4621100A (en) | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
US4543353A (en) | 1981-11-27 | 1985-09-24 | Farmitalia Carlo Erba S.P.A. | Ester and amide derivatives of 13,14-didehydro prostaglandins |
US4599353A (en) | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
EP0187854A4 (en) | 1984-07-13 | 1987-01-22 | Gail S Bazzano | SUBSTITUTED PYRIMIDINE OXIDES USEFUL FOR PROMOTING HAIR GROWTH. |
NZ212914A (en) | 1984-07-31 | 1988-08-30 | Syntex Inc | Tetranorprostaglandin derivatives and pharmaceutical compositions |
JPS6134778U (ja) | 1984-07-31 | 1986-03-03 | 株式会社明電舎 | 電気機器収納箱 |
JPS61126069A (ja) | 1984-11-21 | 1986-06-13 | Res Dev Corp Of Japan | プロスタグランジン誘導体 |
JPS61218510A (ja) | 1985-03-22 | 1986-09-29 | Dai Ichi Seiyaku Co Ltd | 毛髪用剤 |
US4757089A (en) | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
US5863948A (en) | 1985-06-14 | 1999-01-26 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
US4704386A (en) | 1985-08-29 | 1987-11-03 | G. D. Searle & Co. | 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides |
US4883819A (en) | 1986-07-31 | 1989-11-28 | The Trustees Of Columbia University In The City Of New York | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
US4889845A (en) | 1986-06-09 | 1989-12-26 | American Cyanamid Company | Vehicle for topical application of pharmaceuticals |
FI872552A (fi) | 1986-06-09 | 1987-12-10 | American Cyanamid Co | Prostaglandinkomposition foer lokalt bruk. |
US5041439A (en) | 1986-06-13 | 1991-08-20 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US5663203A (en) | 1986-09-11 | 1997-09-02 | Schering Aktiengesellschaft | Agents containing prostacyclin derivatives for topical application |
US5500230A (en) | 1987-01-23 | 1996-03-19 | The General Hospital Corporation | Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators |
US5219885A (en) | 1987-02-16 | 1993-06-15 | Froelich Juergen | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
US4952581A (en) | 1987-04-03 | 1990-08-28 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
US5591887A (en) | 1987-04-30 | 1997-01-07 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
GB8713747D0 (en) | 1987-06-12 | 1987-07-15 | Unilever Plc | Skin treatment composition |
US5166178B1 (en) | 1987-09-18 | 1998-07-21 | R Tech Ueno Ltd | Ocular hypotensive agents |
GB2209939B (en) | 1987-09-18 | 1992-01-02 | R Tech Ueno Ltd | The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents |
SE8703854D0 (sv) | 1987-10-07 | 1987-10-07 | Pharmacia Ab | Prostaglandinderivat for behandling av glaukom eller okuler hypertension |
US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
EP0569046B1 (en) | 1988-09-06 | 2002-11-13 | Pharmacia Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US6187813B1 (en) | 1990-04-10 | 2001-02-13 | Pharmacia & Upjohn Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5321128A (en) | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5194429A (en) | 1988-10-01 | 1993-03-16 | K.K. Ueno Seiyaku Oyo Kenkyujo | Ocular hypotensive agents |
US4968812A (en) | 1989-06-23 | 1990-11-06 | Shell Oil Company | Spirolactonelactams |
JPH0737390B2 (ja) | 1989-08-29 | 1995-04-26 | 久光製薬株式会社 | 軟膏組成物 |
CA1339132C (en) | 1989-09-12 | 1997-07-29 | Johan W. Stjernschantz | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
CA2030345C (en) | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
JPH0720909Y2 (ja) | 1989-12-14 | 1995-05-15 | 松下電器産業株式会社 | コンデンサー |
CA2039420C (en) | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
US5063057A (en) | 1990-09-26 | 1991-11-05 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic capsules |
US5302617A (en) | 1990-04-27 | 1994-04-12 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
DE4024347A1 (de) | 1990-07-27 | 1992-01-30 | Schering Ag | Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
JPH04300833A (ja) | 1991-03-29 | 1992-10-23 | Green Cross Corp:The | プロスタグランジンe1 含有脂肪乳剤充填噴霧剤 |
US5378840A (en) | 1992-04-16 | 1995-01-03 | G. D. Searle & Co. | Substituted dibenzoxazepine compounds |
US5312832A (en) | 1991-05-17 | 1994-05-17 | Allergan, Inc. | Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives |
US5288754A (en) | 1992-02-04 | 1994-02-22 | Allergan, Inc. | Polar C-1 esters of prostaglandins |
US5641494A (en) | 1992-03-20 | 1997-06-24 | Janssen Pharmaceutica N.V. | Agent for regulating the greasiness of the skin |
US5578643A (en) | 1992-05-20 | 1996-11-26 | Loyola University Of Chicago | Protective prostaglandins for use in conjunction with chemotherapeutic agents |
US5422371A (en) | 1992-05-27 | 1995-06-06 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
JP3102141B2 (ja) | 1992-05-29 | 2000-10-23 | 東レ株式会社 | 養毛育毛剤 |
US5817694A (en) | 1992-06-08 | 1998-10-06 | New Pharma International Corp. | 16-methyl-11,16-dihydroxy-9-oxoprost-2,13-dien-1-oic acid and derivatives |
US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5834498A (en) | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
CA2146127C (en) | 1992-10-13 | 2000-06-13 | Louis Desantis, Jr. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
US5332730A (en) | 1992-10-16 | 1994-07-26 | Allergan, Inc. | Azido derivatives of cyclopentane heptanoic or heptenoic acid |
US5340813A (en) | 1992-11-09 | 1994-08-23 | Cell Therapeutics, Inc. | Substituted aminoalkyl xanthine compounds |
DE4238830A1 (de) | 1992-11-17 | 1994-05-19 | Anton Felder | Verfahren zum hydraulischen Verzweigen einer offenen Strömung sowie hydraulisch arbeitende Kanalverzweigung |
US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
US5395932A (en) | 1993-04-30 | 1995-03-07 | G. D. Searle & Co. | 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
US5985597A (en) | 1993-05-26 | 1999-11-16 | Merck Frosst Canada, Inc. | DNA encoding prostaglandin receptor EP1 |
US5869281A (en) | 1993-06-25 | 1999-02-09 | Merck Frosst Canada Inc. | DNA encoding prostaglandin receptor FP |
CA2165953C (en) | 1993-06-25 | 2003-08-19 | Mark Abramovitz | Prostaglandin receptor ep3 and dna encoding it |
US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
US5516652A (en) | 1993-10-06 | 1996-05-14 | Merck Frosst Canada Inc. | DNA encoding prostaglandin receptor IP |
FR2711060B1 (fr) | 1993-10-13 | 1995-11-17 | Oreal | Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet. |
SE9303444D0 (sv) | 1993-10-20 | 1993-10-20 | Kabi Pharmacia Ab | New use of prostaglandins |
WO1995011033A1 (en) | 1993-10-22 | 1995-04-27 | Commonwealth Scientific And Industrial Research Organisation | Polyoxometallates in the treatment of flavivirus infections |
SE9303627D0 (sv) | 1993-11-03 | 1993-11-03 | Kabi Pharmacia Ab | Method and means for prevention of cataract |
US5431881A (en) | 1993-12-10 | 1995-07-11 | Palacios; Henry J. | Treatment of hair loss and dermatological problems |
CA2179399A1 (en) | 1993-12-20 | 1995-06-29 | Kiyoshi Taniguchi | 4,5-diaryloxazole derivatives |
US5545665A (en) | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5458883A (en) | 1994-01-12 | 1995-10-17 | Duke University | Method of treating disorders of the eye |
US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
SE9403158D0 (sv) | 1994-09-21 | 1994-09-21 | Pharmacia Ab | New use of prostaglandins |
US5698733A (en) | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
US5885974A (en) | 1994-12-06 | 1999-03-23 | Michael M. Danielov | Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor |
AU714054B2 (en) | 1995-01-06 | 1999-12-16 | Toray Industries, Inc. | Benzene-fused heterocyclic derivatives and use of the same |
JP3064015B2 (ja) | 1995-01-26 | 2000-07-12 | メルク フロスト カナダ アンド カンパニー | プロスタグランジンレセプターdp |
FR2730811B1 (fr) | 1995-02-17 | 1997-03-21 | Oreal | Procede pour diagnostiquer et/ou suivre l'evolution d'un desordre capillaire et/ou mesurer l'efficacite d'un traitement applique pour combattre un desordre capillaire |
US5885766A (en) | 1995-02-17 | 1999-03-23 | Societe L'oreal S.A. | Method of screening of substances for their effect on the expression of mediators of inflammation in a hair follicle |
EP0825980B1 (en) * | 1995-05-18 | 2001-07-04 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
WO1998021180A1 (en) | 1995-06-07 | 1998-05-22 | Alcon Laboratories, Inc. | Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy |
DE69610481T2 (de) | 1995-06-26 | 2001-04-26 | Teijin Ltd | Prostaglandine und verfahren zu deren herstellung |
TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
HUP9601442A3 (en) | 1995-07-25 | 1999-03-29 | Panacea Biotec Ltd | Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them |
US5661178A (en) | 1995-09-01 | 1997-08-26 | Allergan | Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives |
US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
WO1997015319A1 (en) | 1995-10-23 | 1997-05-01 | Queen's University At Kingston | Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1 |
WO1997023226A1 (en) | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of prostaglandins and miotics for lowering intraocular pressure |
CA2236582C (en) | 1995-12-22 | 2004-08-17 | Alcon Laboratories, Inc. | Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
US5866602A (en) | 1995-12-22 | 1999-02-02 | Alcon Laboratories, Inc. | Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
US5814660A (en) | 1995-12-22 | 1998-09-29 | Alcon Laboratories, Inc. | 9-oxa prostaglandin analogs as ocular hypotensives |
AU7680096A (en) * | 1995-12-22 | 1997-07-17 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5703108A (en) | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
US5741810A (en) | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
US5658897A (en) | 1996-04-08 | 1997-08-19 | Allergan | Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents |
US5990168A (en) | 1996-04-18 | 1999-11-23 | Alberta Cancer Board | Methods and compositions for the treatment of ataxia telangiectasia |
JP3049593B2 (ja) | 1996-05-01 | 2000-06-05 | 株式会社ビメーク | 育毛・養毛剤 |
US6242485B1 (en) | 1996-06-10 | 2001-06-05 | R-Tech Ueno | Endothelin antagonist |
AU3588797A (en) | 1996-07-03 | 1998-01-21 | Board Of Regents Of The University Of Oklahoma, The | Enhancement of skin pigmentation by prostaglandins |
US5792851A (en) | 1996-09-03 | 1998-08-11 | Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Human prostaglandin transporter |
JP4004109B2 (ja) * | 1996-09-17 | 2007-11-07 | 参天製薬株式会社 | 含フッ素プロスタグランジン誘導体および医薬 |
EP0930296B2 (en) | 1996-09-17 | 2005-11-02 | Asahi Glass Company Ltd. | Fluorinated prostaglandin derivatives and medicines |
US5827508A (en) | 1996-09-27 | 1998-10-27 | The Procter & Gamble Company | Stable photoprotective compositions |
WO1998019680A1 (en) | 1996-11-01 | 1998-05-14 | Alcon Laboratories, Inc. | Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma |
WO1998020880A2 (en) | 1996-11-12 | 1998-05-22 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
JP2001504122A (ja) | 1996-11-12 | 2001-03-27 | アルコン ラボラトリーズ,インコーポレイテッド | 眼圧降下剤としてのプロスタグランジン類のcis―δ▲上4▼アナログ |
US6353014B1 (en) | 1996-11-12 | 2002-03-05 | Alcon Laboratories, Inc. | 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension |
JP4248022B2 (ja) | 1996-11-12 | 2009-04-02 | アルコン ラボラトリーズ,インコーポレイテッド | 眼圧降下剤としての15―フルオロプロスタグランジン |
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
IL130333A0 (en) | 1996-12-20 | 2000-06-01 | Pfizer | Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
DE69823852T2 (de) | 1997-02-04 | 2005-05-19 | Johnstone, Murray A., Seattle | Verfahren zur förderung des haarwuchses und entwicklung des haarsystems |
KR20000070903A (ko) | 1997-02-10 | 2000-11-25 | 오노 야꾸힝 고교 가부시키가이샤 | 11,15-o-디알킬프로스타글란딘 e 유도체, 이것의 제조 방법 및 이것을 유효 성분으로 함유하는 약제 |
WO1998037895A1 (fr) | 1997-02-27 | 1998-09-03 | Toray Industries, Inc. | Medicaments permettant d'ameliorer la circulation pulmonaire |
WO1998039293A2 (en) | 1997-03-07 | 1998-09-11 | Alcon Laboratories, Inc. | 13-thia prostaglandins for use in glaucoma therapy |
US6030959A (en) | 1997-04-04 | 2000-02-29 | Monsanto Company | Gastro-specific prodrugs |
JP3217293B2 (ja) | 1997-04-17 | 2001-10-09 | 株式会社アールテック・ウエノ | 発毛・育毛剤 |
IT1291633B1 (it) | 1997-04-22 | 1999-01-11 | Pharmaconsult S A S | Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride |
EP1007028A4 (en) | 1997-05-09 | 2002-06-05 | TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE | |
JP2002501533A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 高眼圧症治療のための眼科用組成物 |
AU7349298A (en) | 1997-06-23 | 1999-01-04 | Pfizer Inc. | Prostaglandin agonists |
SE9702706D0 (sv) | 1997-07-11 | 1997-07-11 | Pharmacia & Upjohn Ab | Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma |
WO1999012556A1 (en) | 1997-09-08 | 1999-03-18 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 DOMAIN EPITOPES CAPABLE OF GENERATING NEUTRALIZING ANTIBODIES |
WO1999012553A1 (en) | 1997-09-08 | 1999-03-18 | Idec Pharmaceuticals Corporation | Methods for producing human antibodies in scid mice using dendritic cells |
CN1269785A (zh) | 1997-09-09 | 2000-10-11 | 普罗克特和甘保尔公司 | 用作fp激活剂的芳香族c16-c20-取代四氢前列腺素 |
WO1999012899A1 (en) * | 1997-09-09 | 1999-03-18 | The Procter & Gamble Company | A process for making prostaglandin f analogs |
DE69824966T2 (de) | 1997-09-09 | 2005-04-07 | Duke University | Aromatische c16-c20-substituierte tetrahydro-prostaglandine verwendbar wie fp agoniste |
WO1999012898A1 (en) | 1997-09-09 | 1999-03-18 | The Procter & Gamble Company | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
EP1035853A1 (en) * | 1997-09-09 | 2000-09-20 | The Procter & Gamble Company | Use of f prostanoid receptor agonists for treating a bone disorder |
ID24840A (id) | 1997-09-09 | 2000-08-24 | Procter & Gamble | Proses untuk membuat bahan antara epoksida |
EP1011709A4 (en) | 1997-09-09 | 2003-06-18 | Univ California | APOPTOSE INHIBITION BY PROSAPOSIN RECEPTORAGONISTS |
AUPO907697A0 (en) | 1997-09-09 | 1997-10-02 | Day, Robert Edward | Chemical supplementation of bone |
RS49707B (sr) | 1997-09-09 | 2007-12-31 | F.Hoffmann-La Roche Ag., | Primena polipeptidnog analoga peptida srodnog paratireoidnom hormonu i njegovih soli za proizvodnju medikamenata za lečenje preloma kostiju |
KR20010023840A (ko) * | 1997-09-09 | 2001-03-26 | 데이비드 엠 모이어 | 비천연 선택성 fp 아고니스트를 이용한 골 부피 증가 방법 |
ATE363914T1 (de) | 1997-09-09 | 2007-06-15 | Curis Inc | Synergistische wirkung des ob/bmp morphogens und gdnf/ngf neurotropher faktoren |
AU9312598A (en) | 1997-09-10 | 1999-03-29 | Allegheny University Of The Health Sciences | Inhibitors of collagen assembly |
WO1999012552A1 (en) | 1997-09-10 | 1999-03-18 | Merck & Co., Inc. | 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS |
US6331319B1 (en) | 1997-09-11 | 2001-12-18 | Purdue Research Foundation | Galactosidase modified submucosal tissue |
WO1999012563A2 (en) | 1997-09-11 | 1999-03-18 | The Governemnt Of The United States Of America, Represented By The Department Of Health And Human Services | Mucosal cytotoxic t lymphocyte responses |
US6326170B1 (en) | 1997-09-12 | 2001-12-04 | Smithkline Beecham Corp. | Prokaryotic polynucleotides, polypeptides and their uses |
EP0970697A4 (en) | 1997-09-17 | 2001-02-21 | Toray Industries | MATERIAL FOR CERVICAL MATURATION |
ATE253047T1 (de) | 1997-09-19 | 2003-11-15 | Shionogi & Co | Verbindungen mit (2.2.1)bicyclischer molekülstruktur |
US6124314A (en) | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
JP2001520999A (ja) | 1997-10-28 | 2001-11-06 | アシビ, エルエルシー | 女性の性的機能不全の処置 |
AUPP010397A0 (en) | 1997-10-30 | 1997-11-20 | Vaisman, Jakov | Method and composition for treatment of sexual dysfunction |
AU1373499A (en) | 1997-11-14 | 1999-06-07 | United Therapeutics Corporation | Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease |
US5877211A (en) | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
US6099870A (en) | 1997-12-18 | 2000-08-08 | Johnson & Johnson Consumer Companies, Inc. | Methods for improving the health of hair and scalp |
CA2314369A1 (en) | 1997-12-18 | 1999-06-24 | Nathan Earl Scott | Prostaglandin e2/f2.alpha. combination for treating impotence and enhancing sexual arousal |
US5955575A (en) | 1997-12-22 | 1999-09-21 | Hopital Sainte-Justine | Antagonists of G-protein-coupled receptor |
WO1999032441A1 (en) | 1997-12-22 | 1999-07-01 | Alcon Laboratories, Inc. | 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension |
WO1999032641A1 (en) | 1997-12-22 | 1999-07-01 | Unilever N.V. | A process for site-directed integration of multiple copies of a gene in a mould |
KR20010033538A (ko) | 1997-12-25 | 2001-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | ω-시클로알킬-프로스타글란딘 E2 유도체 |
GB2330307A (en) | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
EP1071648A2 (en) | 1998-03-13 | 2001-01-31 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
TR200002808T2 (tr) | 1998-03-31 | 2001-01-22 | The Procter & Gamble Company | İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri |
US6444840B1 (en) | 1998-03-31 | 2002-09-03 | The Procter & Gamble Co. | C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists |
ES2244208T3 (es) | 1998-03-31 | 2005-12-01 | Duke University | Prostaglandinas oximil e hidroxilamino c11 utilizados como antagonistas fp. |
EP1083168B1 (en) | 1998-05-25 | 2003-10-22 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivative |
US6458549B2 (en) | 1998-06-11 | 2002-10-01 | Winthrop-University Hospital | Methods of diagnosing renal salt wasting syndrome and Alzheimer's disease and methods of treating the same |
US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6187818B1 (en) | 1998-06-17 | 2001-02-13 | Pharmacia & Upjohn Company | Prostaglandins formulation and process |
WO2000002450A1 (en) | 1998-07-08 | 2000-01-20 | Fibrogen, Inc. | Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives |
CN1146423C (zh) | 1998-07-14 | 2004-04-21 | 阿尔康实验室公司 | 前列腺素产品 |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
AU5114499A (en) | 1998-07-21 | 2000-02-14 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2002521332A (ja) | 1998-07-21 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼薬組成物 |
US6284234B1 (en) | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
WO2000009557A1 (fr) | 1998-08-12 | 2000-02-24 | Kazusa Dna Research Institute Foundation | Nouveau gene et nouvelle proteine pgth codee par ce gene |
US6586468B1 (en) | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
AUPP608898A0 (en) | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
US6121253A (en) | 1998-11-20 | 2000-09-19 | Merck Frosst Canada & Co. | Prostaglandin conjugates for treating or preventing bone disease |
CZ20013117A3 (cs) | 1999-03-01 | 2002-06-12 | Pfizer Products Inc. | Oxamové kyseliny a jejich deriváty jako ligandy thyreoidního receptoru |
CN1382121A (zh) | 1999-03-05 | 2002-11-27 | 宝洁公司 | C16不饱和的fp选择性前列腺素类似物 |
JP4834224B2 (ja) | 1999-03-05 | 2011-12-14 | デューク ユニバーシティ | C16不飽和fp−選択的プロスタグランジン類縁体 |
AU3082999A (en) | 1999-03-12 | 2000-10-04 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
IL147771A0 (en) | 1999-08-04 | 2002-08-14 | Procter & Gamble | Novel 2-decarboxy-2-phosphinico prostaglandin f analogs |
US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
US6548535B2 (en) | 2000-01-18 | 2003-04-15 | Merck & Co., Inc. | Method for treating ocular hypertension |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
EP1186287A1 (en) | 2000-03-31 | 2002-03-13 | Toray Industries, Inc. | Hair growth or hair formation controlling agents |
US20020146439A1 (en) | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
FR2812190B1 (fr) | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
EP1361867B1 (en) | 2001-02-22 | 2007-03-21 | Jagotec AG | Fibrate-statin combinations with reduced fed-fasted effects |
EP1298223A3 (en) | 2001-09-28 | 2003-07-23 | Pfizer Products Inc. | Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene |
SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
DE60307607T2 (de) | 2002-03-18 | 2007-08-09 | Pfizer Products Inc., Groton | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten |
US7186707B2 (en) | 2002-04-01 | 2007-03-06 | University Of Florida | Prodrugs for use as ophthalmic agents |
US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US20030199590A1 (en) | 2002-07-25 | 2003-10-23 | Cagle Gerald D | Prostaglandin analogues for promotion of hair growth |
US20050058614A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides |
US7070768B2 (en) | 2003-09-25 | 2006-07-04 | Allergan, Inc. | Method for imparting artificial tan to human skin |
WO2005053683A1 (en) | 2003-11-26 | 2005-06-16 | Duke University | A method of preventing or treating glaucoma |
US7288029B1 (en) | 2005-01-19 | 2007-10-30 | Gkn Driveline North America, Inc. | Propshaft with crash-worthiness |
WO2006047466A2 (en) | 2004-10-21 | 2006-05-04 | Duke University | Ophthamological drugs |
WO2007125818A1 (ja) | 2006-04-24 | 2007-11-08 | Jsr Corporation | 重合体及びそれを含有する感光性樹脂組成物 |
US20070254920A1 (en) | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
US20090018204A1 (en) | 2007-07-13 | 2009-01-15 | Brinkenhoff Michael C | Composition and method for enhancing hair growth |
US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
-
2000
- 2000-02-29 JP JP2000602208A patent/JP4834224B2/ja not_active Expired - Fee Related
- 2000-02-29 MX MXPA01008955A patent/MXPA01008955A/es not_active Application Discontinuation
- 2000-02-29 CN CN00807185A patent/CN1350521A/zh active Pending
- 2000-02-29 HU HU0200258A patent/HUP0200258A2/hu unknown
- 2000-02-29 CA CA2364948A patent/CA2364948C/en not_active Expired - Lifetime
- 2000-02-29 ES ES00917686T patent/ES2232434T3/es not_active Expired - Lifetime
- 2000-02-29 WO PCT/US2000/005301 patent/WO2000051980A1/en not_active Application Discontinuation
- 2000-02-29 DE DE60015508T patent/DE60015508T2/de not_active Expired - Lifetime
- 2000-02-29 NZ NZ513825A patent/NZ513825A/en unknown
- 2000-02-29 PL PL00350917A patent/PL350917A1/xx unknown
- 2000-02-29 BR BR0008776-9A patent/BR0008776A/pt not_active Application Discontinuation
- 2000-02-29 IL IL14512200A patent/IL145122A0/xx unknown
- 2000-02-29 AU AU38620/00A patent/AU766163B2/en not_active Expired
- 2000-02-29 EP EP00917686A patent/EP1159266B1/en not_active Expired - Lifetime
- 2000-02-29 CZ CZ20013174A patent/CZ20013174A3/cs unknown
- 2000-02-29 AT AT00917686T patent/ATE281432T1/de not_active IP Right Cessation
- 2000-02-29 KR KR1020017011293A patent/KR20010108316A/ko not_active Application Discontinuation
- 2000-03-06 CO CO00016012A patent/CO5160251A1/es unknown
-
2001
- 2001-08-31 NO NO20014241A patent/NO20014241L/no not_active Application Discontinuation
- 2001-09-04 US US09/946,021 patent/US6586463B2/en not_active Ceased
-
2009
- 2009-06-05 US US12/479,532 patent/USRE43372E1/en not_active Expired - Lifetime
-
2010
- 2010-09-16 JP JP2010208198A patent/JP2011037861A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108084074A (zh) * | 2017-12-25 | 2018-05-29 | 厦门欧瑞捷生物科技有限公司 | 一种简便高效合成地诺前列素的方法 |
CN108084074B (zh) * | 2017-12-25 | 2018-11-20 | 厦门欧瑞捷生物科技有限公司 | 一种简便高效合成地诺前列素的方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2002538139A (ja) | 2002-11-12 |
HUP0200258A2 (hu) | 2002-05-29 |
JP4834224B2 (ja) | 2011-12-14 |
ES2232434T3 (es) | 2005-06-01 |
CO5160251A1 (es) | 2002-05-30 |
ATE281432T1 (de) | 2004-11-15 |
BR0008776A (pt) | 2001-12-18 |
JP2011037861A (ja) | 2011-02-24 |
US6586463B2 (en) | 2003-07-01 |
AU766163B2 (en) | 2003-10-09 |
IL145122A0 (en) | 2002-06-30 |
AU3862000A (en) | 2000-09-21 |
CA2364948A1 (en) | 2000-09-08 |
EP1159266B1 (en) | 2004-11-03 |
CZ20013174A3 (cs) | 2002-02-13 |
NZ513825A (en) | 2001-09-28 |
KR20010108316A (ko) | 2001-12-07 |
CA2364948C (en) | 2011-04-26 |
USRE43372E1 (en) | 2012-05-08 |
NO20014241L (no) | 2001-11-05 |
DE60015508T2 (de) | 2005-04-21 |
PL350917A1 (en) | 2003-02-10 |
MXPA01008955A (es) | 2002-04-24 |
DE60015508D1 (de) | 2004-12-09 |
NO20014241D0 (no) | 2001-08-31 |
US20020037913A1 (en) | 2002-03-28 |
EP1159266A1 (en) | 2001-12-05 |
WO2000051980A1 (en) | 2000-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1269786A (zh) | 用作fp激活剂的芳香族c16-c20-取代四氢前列腺素 | |
CN1350521A (zh) | C16不饱和的fp选择性前列腺素类似物 | |
CN1269784A (zh) | 用作fp激活剂的芳香族c16-c20-取代四氢前列腺素 | |
JP6149975B2 (ja) | 二環式化合物およびその医薬用途 | |
CN1169528C (zh) | 对治疗青光眼无副作用的前列腺素衍生物 | |
CN1269785A (zh) | 用作fp激活剂的芳香族c16-c20-取代四氢前列腺素 | |
CN1812963A (zh) | 用于治疗阿尔茨海默病的N-烷基苯基甲酰胺β分泌酶抑制剂 | |
CN1835936A (zh) | 用于治疗阿尔茨海默氏病的大环β-分泌酶抑制剂 | |
CN1176072C (zh) | 维生素d3类似物 | |
NO317060B1 (no) | Fluor-holdig prostaglandinderivat, anvendelse derav samt medisiner inneholdende derivatet | |
CN1291100A (zh) | 作为治疗剂的环戊烷庚(烯)酸,2-杂芳基烯基衍生物 | |
CN1382121A (zh) | C16不饱和的fp选择性前列腺素类似物 | |
CN104662021A (zh) | 新的双环吡啶酮类 | |
JP5835236B2 (ja) | 二環式化合物およびその医薬用途 | |
JP5907077B2 (ja) | 二環式化合物およびその医薬用途 | |
CN1264820C (zh) | 降眼压类脂类 | |
CN1144783C (zh) | 前列腺素衍生物 | |
HRP20020161A2 (en) | New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments | |
CN1337931A (zh) | 类维生素a拮抗剂及其用途 | |
CN1295560A (zh) | 用作药物的c11肟基和羟氨基前列腺素 | |
CA2111447C (en) | Hypoglycemic thiazolidinediones and intermediates | |
CN1295559A (zh) | 用作fp激动剂的c11肟基和羟氨基前列腺素 | |
CN1029400C (zh) | 侧链系维生素d衍生物的制备方法 | |
CN1232452A (zh) | Nmda(n-甲基-d-天冬氨酸)拮抗剂 | |
CN1191528A (zh) | 具有褪黑激素受体结合亲合力的苯并环烯化合物,其生产方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |